ERYTECH Sells U.S. Manufacturing Facility and Enters Long-Term Supply Agreement with Catalent Post author:Marianne Duparc Post published:April 25, 2022 Post category:Newsroom ERYTECH Pharma announced the sale of its U.S. manufacturing facility to Catalent, a leading contract development and manufacturing organization (CDMO) in advanced therapies. You Might Also Like ERYTECH’S COMBINED SHAREHOLDERS’ MEETING ON JUNE 25, 2021 May 25, 2021 Erytech Announces 2016 Financial Calendar February 8, 2016 ERYTECH engages in collaborative partnership with EU Horizon 2020 EVIDENCE consortium May 5, 2020